Jonathan R. Strosberg, MD

Jonathan R. Strosberg, MD, medical oncologist, Moffitt Cancer Center, discusses the results of the phase III NETTER-1 trial. The trial looked at radionuclide therapy Lu-Dotatate (177Lutetium DOTATATE; Lutathera) in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Videos

The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors. Strosberg says this targeted therapy is especially useful due to neuroendocrine tumors generally having high-expressing somatostatin expressers.

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors.

Jonathan R. Strosberg, MD | Authors

Articles

Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs

Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine Tumors